Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dexmethylphenidate.

Gillian M Keating1, David P Figgitt

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|September 7, 2002
PubMed
Summary
This summary is machine-generated.

Dexmethylphenidate, the active isomer of methylphenidate, effectively treats attention deficit hyperactivity disorder (ADHD) in children. Studies show significant symptom improvement and better treatment adherence compared to placebo.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Afatinib in advanced NSCLC: a profile of its use.

Drugs & therapy perspectives : for rational drug selection and use·2019
Same author

Afatinib in advanced NSCLC: a profile of its use.

Drugs & therapy perspectives : for rational drug selection and use·2018
Same author

Ticagrelor: A Review in Long Term Secondary Prevention of Cardiovascular Events.

Drugs·2017
Same author

Eluxadoline: A Review in Diarrhoea-Predominant Irritable Bowel Syndrome.

Drugs·2017
Same author

Sorafenib: A Review in Hepatocellular Carcinoma.

Targeted oncology·2017
Same author

Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex<sup>®</sup>): A Review in Multiple Sclerosis-Related Spasticity.

Drugs·2017
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Neuroscience
  • Pediatrics

Background:

  • Dexmethylphenidate is the d-enantiomer of methylphenidate, a widely used treatment for attention deficit hyperactivity disorder (ADHD).
  • Understanding the efficacy and tolerability of dexmethylphenidate is crucial for managing ADHD in pediatric populations.

Purpose of the Study:

  • To evaluate the efficacy and safety of dexmethylphenidate in children diagnosed with ADHD.
  • To compare the effectiveness of dexmethylphenidate against methylphenidate and placebo.

Main Methods:

  • A 4-week, double-blind trial involving 132 children with ADHD.
  • Teacher and parent ratings of ADHD symptoms using Swanson, Nolan and Pelham (SNAP)-ADHD and Clinical Global Impression-Improvement of Illness scales.
  • A double-blind, treatment-withdrawal trial in 75 children with ADHD.

Related Experiment Videos

  • A noncomparative study assessing symptom control and duration of effect in 22 children with ADHD.

    • Main Results:

    • Dexmethylphenidate and methylphenidate showed significantly greater improvements in teacher-rated SNAP-ADHD scores compared to placebo.
    • Both active treatments resulted in more participants being rated as much or very much improved.
    • Parent-rated SNAP-ADHD scores decreased significantly more with dexmethylphenidate and methylphenidate at specific time points.
    • Treatment failure rates were significantly lower for dexmethylphenidate compared to placebo (17.1% vs 61.5%).
    • In a separate study, dexmethylphenidate controlled ADHD symptoms throughout the school day for 68% of children (teacher-rated) and 86% (parent-rated), with median durations of 6.3 and 7.5 hours, respectively.

    Conclusions:

    • Dexmethylphenidate demonstrates significant efficacy in improving ADHD symptoms in children aged 6 years and older.
    • The drug is generally well-tolerated, with adverse events consistent with methylphenidate agents.
    • Dexmethylphenidate offers a viable treatment option for ADHD, showing sustained symptom control and reduced treatment failure.